|
시장보고서
상품코드
2075899
간암 치료제 시장 : 치료법별, 약제 유형별, 치료 단계별, 지역별Liver Cancer Therapeutics Market, By Therapeutic Modality, By Drug Type, By Treatment Line, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
간암 치료제 시장은 2026년에 89억 8,000만 달러 규모에 이를 것으로 추정되며, 2033년까지 169억 5,000만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 9.5%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 89억 8,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) : | 9.50% | 시장 규모 예측(2033년) : | 169억 5,000만 달러 |
세계 간암 치료제 시장은 표적 치료, 면역 치료, 화학 요법 등 광범위한 치료법 범주를 아우르며, 저분자 화합물, 단일클론 항체, 항체-약물 복합체(ADC) 등의 용도로 활용되고 있습니다. 수요는 1차 및 2차 치료법으로 채택되는 것 외에도, 보다 효율적이고 신뢰할 수 있는 솔루션에 대한 필요성에 힘입어 증가하고 있습니다. 지속적인 기술 발전과 최종 사용자의 요구 증가가 이 시장의 성장을 주도하고 있습니다.
시장 역학 :
저분자 화합물 및 단일클론 항체의 사용 확대, 최종 사용자 수요 증가, 그리고 효율성과 성능 향상을 위한 지속적인 노력이 전 세계 간암 치료제 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 이용 가능한 선택의 폭이 넓어짐에 따라, 더 다양한 사용자층이 이러한 솔루션을 이용할 수 있게 되었습니다.
예를 들어, 각 기업은 1차 치료 및 2차 치료에서 변화하는 요건에 대응하기 위해 제품 포트폴리오를 확대되고 있습니다. 또한, 혁신 및 신기술 통합에 대한 투자 확대에 힘입어, 예측 기간 동안 시장 참여자들에게 새로운 성장 기회가 창출될 것으로 전망됩니다.
본 조사의 주요 특징 :
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 세계의 간암 치료제 시장의 주요 기업 프로파일을 소개했습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 이 책 '세계의 간암 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 간암 치료제 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 개요
제3장 시장 역학, 규제 및 동향 분석
제4장 간암 치료제 시장 : 치료 모달리티별(2026-2033년)
제5장 간암 치료제 시장 : 약제 유형별(2026-2033년)
제6장 간암 치료제 시장 : 치료 라인별(2026-2033년)
제7장 간암 치료제 시장 : 지역별(2026-2033년)
제1장 경쟁 구도
제2장 섹션
AJY 26.07.09Liver Cancer Therapeutics Market is estimated to be valued at USD 8.98 billion in 2026 and is expected to reach USD 16.95 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 8.98 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.50% | 2033 Value Projection: | USD 16.95 billion |
The global liver cancer therapeutics market covers a broad set of therapeutic modality categories, including Targeted Therapy, Immunotherapy, and Chemotherapy, used across applications such as Small Molecules, Monoclonal Antibodies, and Antibody-Drug Conjugates (ADC). Demand is supported by adoption among First Line, and Second Line and the need for more efficient, reliable solutions. Continued technological advancement and rising end-user requirements are shaping the growth of this market.
Market Dynamics:
Growing adoption across Small Molecules, and Monoclonal Antibodies, rising end-user demand, and a continued focus on improving efficiency and performance are major factors expected to drive growth of the global liver cancer therapeutics market. A wider range of available options is making these solutions accessible to a broader base of users.
For instance, companies are expanding their portfolios to address evolving requirements across First Line, and Second Line. Moreover, increasing investment in innovation and new technology integration is expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global liver cancer therapeutics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Gilead Sciences, Bristol-Myers Squibb, Bayer AG, Merck & Co., Novartis AG, Eisai Co, Ltd., AstraZeneca PLC, Pfizer Inc., Ipsen, Exelixis, NGM Biopharmaceuticals, HUTCHMED, Zai Lab, Genfit, and BeiGene, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global liver cancer therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liver cancer therapeutics market.
Detailed Segmentation:
- Global Liver Cancer Therapeutics Market, By Therapeutic Modality (Revenue, USD Bn, 2021 - 2033)
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Locoregional Therapy
- Others
- Global Liver Cancer Therapeutics Market, By Drug Type (Revenue, USD Bn, 2021 - 2033)
- Small Molecules
- Monoclonal Antibodies
- Antibody-Drug Conjugates (ADC)
- Cell-based Therapies
- Others
- Global Liver Cancer Therapeutics Market, By Treatment Line (Revenue, USD Bn, 2021 - 2033)
- First Line
- Second Line
- Third Line and Beyond
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Gilead Sciences*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Bristol-Myers Squibb
- Bayer AG
- Merck & Co.
- Novartis AG
- Eisai Co, Ltd.
- AstraZeneca PLC
- Pfizer Inc.
- Ipsen
- Exelixis
- NGM Biopharmaceuticals
- HUTCHMED
- Zai Lab
- Genfit
- BeiGene
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Therapeutic Modality
- Market Snapshot, By Drug Type
- Market Snapshot, By Treatment Line
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Liver Cancer Therapeutics Market By Therapeutic Modality, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Locoregional Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Liver Cancer Therapeutics Market By Drug Type, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Small Molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Antibody-Drug Conjugates (ADC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Cell-based Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Liver Cancer Therapeutics Market By Treatment Line, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- First Line
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Second Line
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Third Line and Beyond
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Liver Cancer Therapeutics Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Line, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Line, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Line, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Line, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Line, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
1. Competitive Landscape
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ipsen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Exelixis
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- NGM Biopharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- HUTCHMED
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Zai Lab
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Genfit
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- BeiGene
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
2. Section
- Research Methodology
- About Us
